PremiumThe FlyVerastem announces positive Phase 1/2 safety and efficacy results in PDAC Verastem’s Strategic Focus and FDA Approval Drive Buy Rating Verastem files to sell 3.43M shares of common stock for holders PremiumThe FlyVerastem price target raised to $14 from $10 at H.C. Wainwright Verastem Gains FDA Approval for New Cancer Treatment Verastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC Therapy PremiumPre-EarningsIs VSTM a Buy, Before Earnings? Verastem participates in a conference call with Cantor Fitzgerald Verastem Announces $75M Private Placement Agreement 
